Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 14/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 11/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 8/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.83 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.83 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5144149 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL5144151 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL9006835 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL4611391 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| Bromide SCHEMBL29460100 | 0.99 | ADRB3 (0.98) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| Bromide SCHEMBL9317314 | 0.99 | ADRB3 (0.98) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| Bromide SCHEMBL9799484 | 0.99 | ADRB3 (0.98) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| Trifluoroacetic Acid SCHEMBL9318455 | 0.94 | ADRB3 (0.89) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL9812022 | 0.91 | ADRB3 (0.84) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL9436811 | 0.91 | ADRB3 (0.84) | ADRB3ADRB2ADRB1GLACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217706-B2 | Propanolamine derivatives | ASTELLAS PHARMA INC. (JP) | 2007-05-15 | — | — | US | disclosed |
| EP-1382333-A2 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-6495546-B1 | SUCH AS 1-(N-BENZYL-N-(3-METHOXY-6,7,8,9-TETRAHYDRO-5H-BENZO-CYCLOHEPTEN-6-YL)AMINO)-3-PHENOXY-2-PROPANOL; ADRENERGIC RECEPTOR AGONISTS; ANTIULCEROUS, LIPOLYTIC, ANTIURINARY INCONTINENCE AND ANTIPOLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-20020120148-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120148-A1 | Propanolamine derivatives | AMY2A, PNMT, PNLIP | ADRB3 12/4885ADRB2 7/4885ADRB1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.